Pulmonary drug delivery is at a crossroads. While pressurised metered-dose and dry powder inhalers have shaped respiratory medicine for decades, both technologies show their limits when applied to modern, complex molecules. The obstacle is rarely the active pharmaceutical ingredient itself. It is the lactose carriers, chemical propellants, or inconsistent aerosol characteristics that define legacy systems and prevent reliable dosing. Here, thermal vaporisation of liquid activ